For the quarter ended September 2025, Jazz Pharmaceuticals (JAZZ Quick QuoteJAZZ - Free Report) reported revenue of $1.13 billion, up 6.7% over the same period last year. EPS came in at $8.13, compared to $6.61 in the year-ago quarter.

The reported revenue represents a surprise of +2.16% over the Zacks Consensus Estimate of $1.1 billion. With the consensus EPS estimate being $5.74, the EPS surprise was +41.64%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Jazz performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Total revenues- Oncology- Vyxeos: $37.58 million compared to the $39.17 million average estimate based on eight analysts. The reported number represents a change of +9.5% year over year.
• Total revenues- Oncology- Defitelio/defibrotide: $51.75 million versus $56.1 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a -21.4% change.
• Total revenues- Neuroscience- Oxybate- Xywav: $431.41 million compared to the $434.72 million average estimate based on eight analysts. The reported number represents a change of +11.1% year over year.
• Total revenues- Neuroscience- Epidiolex/Epidyolex: $302.61 million versus the eight-analyst average estimate of $273.8 million. The reported number represents a year-over-year change of +20.3%.
• Total revenues- Neuroscience- Sativex: $4.75 million compared to the $4.84 million average estimate based on eight analysts. The reported number represents a change of +3.6% year over year.
• Total revenues- Neuroscience- Oxybate (Xywav & Xyrem): $467.07 million versus $466.98 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +4.6% change.
• Total revenues- Neuroscience- Total: $774.43 million versus $745.62 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +10.2% change.
• Total revenues- Oncology- Total: $287.84 million compared to the $291.13 million average estimate based on eight analysts. The reported number represents a change of +1.1% year over year.
• Total revenues- Oncology- Rylaze/Enrylaze: $99.87 million versus the eight-analyst average estimate of $103.76 million. The reported number represents a year-over-year change of +1.1%.
• Total revenues- Oncology- Zepzelca: $79.3 million versus $82.01 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a -7.6% change.
• Revenues- Product sales, net: $1.06 billion versus $1.04 billion estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +7.6% change.
• Total revenues- Other: $2.14 million versus the eight-analyst average estimate of $3.32 million. The reported number represents a year-over-year change of -3.9%.

View all Key Company Metrics for Jazz here>>>

Shares of Jazz have returned +0.4% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.